Equine Piroplasmosis: Diagnostic Tools for Babesia caballi and Theileria equi

Introduction

Equine piroplasmosis (EP) is a tick-borne protozoal disease of equids caused by the intraerythrocytic apicomplexan parasites Babesia caballi and Theileria equi (formerly Babesia equi). The disease is endemic in many tropical and subtropical regions and poses a significant threat to international horse movement due to strict import regulations in non-endemic countries. Accurate diagnosis is critical for clinical management, epidemiological surveillance, and trade compliance. This article provides an exhaustive review of the diagnostic tools available for EP, focusing on the comparative performance of competitive enzyme-linked immunosorbent assay (cELISA), indirect fluorescent antibody test (IFAT), and polymerase chain reaction (PCR) in detecting acute and chronic infections. Vector tick species, geographic risk distribution, and international trade regulations are also discussed.

Etiological Agents and Pathogenesis

Babesia caballi and Theileria equi are obligate intraerythrocytic parasites transmitted by ixodid ticks. T. equi is more pathogenic and can cause severe hemolytic anemia, hemoglobinuria, and death, whereas B. caballi often results in milder or subclinical infections. Both parasites undergo asexual multiplication (merogony) within equine erythrocytes, leading to erythrocyte lysis and subsequent anemia. Chronic carriers are common and serve as reservoirs for tick transmission. The parasites can be differentiated morphologically: B. caballi typically appears as paired piriform merozoites (2.0–3.0 µm), while T. equi forms a characteristic Maltese cross tetrad arrangement (four merozoites) [1, 2].

Vector Tick Species and Geographic Risk

EP is transmitted primarily by ticks of the genera Dermacentor, Rhipicephalus, and Hyalomma. The principal vectors include Dermacentor nitens (tropical horse tick) in the Americas, Dermacentor variabilis in North America, Rhipicephalus microplus (cattle tick) in tropical regions, and Hyalomma spp. in Africa, Asia, and southern Europe [3, 4]. Transovarial transmission occurs for B. caballi but not for T. equi; transstadial transmission is documented for both [5].

Geographic risk is highest in regions where these tick vectors are endemic: sub-Saharan Africa, the Middle East, Central and South America, the Caribbean, southern Europe, and parts of Asia (including India, China, and Southeast Asia). Sporadic outbreaks have occurred in non-endemic areas such as the United States and Australia due to importation of infected horses or infected ticks [6, 7]. Climate change is expanding the range of competent tick vectors, increasing the risk of EP emergence in previously free areas [8].

International Trade Regulations

The World Organisation for Animal Health (WOAH) classifies EP as a notifiable disease. International movement of horses from endemic to non-endemic countries requires proof of freedom from infection. Standard pre-export testing includes serological assays (cELISA or IFAT) and, in some cases, PCR. The WOAH Terrestrial Manual provides guidelines for diagnostic testing [9]. For example, the United States Department of Agriculture (USDA) requires a negative cELISA result for horses imported from countries where EP is known to occur. Horses that test positive are subject to quarantine, treatment, or permanent restriction [10]. The European Union (EU) mandates testing for T. equi and B. caballi using validated serological methods, with a 30-day quarantine period for positive animals [11].

Diagnostic Tools

Competitive Enzyme-Linked Immunosorbent Assay (cELISA)

cELISA is the WOAH-prescribed serological test for EP. It detects antibodies against parasite-specific surface antigens, typically the merozoite surface protein (MSP) or the equi merozoite antigen (EMA) for T. equi, and the B. caballi rhoptry-associated protein (RAP-1) [12, 13]. The assay uses a monoclonal antibody that competes with equine antibodies for binding to the recombinant antigen. A reduction in signal indicates a positive result.

Advantages: High sensitivity and specificity (reported >95% for both parasites in experimental infections) [14, 15]. Suitable for high-throughput screening. Can differentiate between B. caballi and T. equi infections using species-specific antigens.

Limitations: Cannot distinguish between active and past infection; antibodies may persist for years after clearance [16]. Cross-reactivity with other piroplasms is minimal but has been reported in some studies [17]. Requires specialized laboratory equipment and trained personnel.

Indirect Fluorescent Antibody Test (IFAT)

IFAT uses whole fixed parasites (cultured or from infected erythrocytes) as antigen. Equine serum is applied, and bound antibodies are detected using a fluorescently labeled anti-equine immunoglobulin. The test is read microscopically.

Advantages: Relatively simple and inexpensive. Can be used for both species simultaneously if mixed antigen slides are prepared [18]. Useful for small-scale testing in resource-limited settings.

Limitations: Subjective interpretation; requires experienced microscopists. Lower specificity than cELISA due to potential cross-reactivity with other hemoparasites [19]. Sensitivity is lower in chronic infections with low antibody titers [20]. Not suitable for high-throughput automation.

Polymerase Chain Reaction (PCR)

PCR detects parasite DNA in blood samples. Target genes include the 18S rRNA gene, the ema-1 gene for T. equi, and the rap-1 gene for B. caballi [21, 22]. Real-time PCR (qPCR) allows quantification of parasitemia. Nested PCR and multiplex PCR formats are available for simultaneous detection of both species [23].

Advantages: High sensitivity and specificity; can detect subclinical carriers with very low parasitemia [24]. Differentiates active infection from past exposure. Provides rapid results (within hours). Useful for confirming serological positives and for monitoring treatment efficacy.

Limitations: Requires specialized equipment and reagents. False negatives can occur due to low parasitemia, sample degradation, or PCR inhibitors [25]. Does not distinguish between viable and non-viable organisms. Cost per test is higher than serology.

Comparison of Diagnostic Methods

Diagnostic Workflow

The following Mermaid diagram illustrates a recommended diagnostic algorithm for equine piroplasmosis in a clinical or trade setting.

flowchart TD
    A[Blood sample from horse], > B{Clinical suspicion?}
    B, >|Yes| C[Perform PCR and cELISA]
    B, >|No (trade/import)| D[Perform cELISA]
    C, > E{PCR positive?}
    E, >|Yes| F[Active infection confirmed]
    E, >|No| G{cELISA positive?}
    G, >|Yes| H[Chronic carrier or past exposure]
    G, >|No| I[No evidence of infection]
    D, > J{cELISA positive?}
    J, >|Yes| K[Perform PCR for confirmation]
    J, >|No| L[Negative - eligible for movement]
    K, > M{PCR positive?}
    M, >|Yes| N[Active infection - quarantine/treat]
    M, >|No| O[Seropositive carrier - manage per regulations]

Discussion

The choice of diagnostic test depends on the clinical context and purpose. For acute clinical cases, PCR is the most sensitive method because it detects DNA before seroconversion (which typically occurs 7–14 days post-infection) [26]. cELISA and IFAT may be negative in the first week of infection. For chronic carrier detection, serology (cELISA) is preferred due to the persistence of antibodies, although PCR can also detect low-level parasitemia in many carriers [27].

In trade settings, cELISA is the standard because it is high-throughput, objective, and has well-established performance characteristics. However, false positives can occur due to cross-reactivity with other tick-borne pathogens such as Anaplasma phagocytophilum (see Anaplasma phagocytophilum in Livestock and Companion Animals: Diagnostics and Tick-Borne Epidemiology). Confirmatory PCR is recommended for seropositive animals to rule out active infection [28].

IFAT remains useful in field settings where advanced laboratory infrastructure is unavailable, but its lower specificity and subjective interpretation limit its reliability for official certification. Multiplex PCR panels that include other equine pathogens (e.g., West Nile Virus in Horses: Veterinary Reference) can be valuable for differential diagnosis in febrile horses [29].

Treatment of EP with imidocarb dipropionate can clear B. caballi infection but may not eliminate T. equi; treated horses often remain seropositive for months to years [30]. Therefore, post-treatment monitoring should include both PCR (to confirm clearance) and serology (to track antibody decline). A negative PCR result after treatment does not guarantee elimination of the parasite, as sequestration in tissues may occur [31].

Conclusion

Equine piroplasmosis remains a major constraint to international horse movement and a cause of significant morbidity in endemic areas. Accurate diagnosis requires a combination of serological and molecular methods. cELISA is the gold standard for trade, while PCR is essential for acute case confirmation and carrier detection. IFAT serves as a cost-effective alternative in low-resource settings but should be interpreted with caution. Ongoing surveillance, vector control, and adherence to WOAH guidelines are critical for preventing the spread of EP into non-endemic regions.

References

[1] Brüning A. Equine piroplasmosis: an update on diagnosis, treatment and prevention. Br Vet J. 1996;152(2):139-151.

[2] Mehlhorn H, Schein E. The piroplasms: life cycle and sexual stages. Adv Parasitol. 1984;23:37-103.

[3] Scoles GA, Ueti MW. Vector ecology of equine piroplasmosis. Annu Rev Entomol. 2015;60:561-580.

[4] Stiller D, Coan ME. Recent developments in elucidating tick vector relationships for anaplasmosis and equine piroplasmosis. Vet Parasitol. 1995;57(1-3):97-108.

[5] Ueti MW, Palmer GH, Scoles GA, et al. Persistently infected horses are reservoirs for intrastadial tick-borne transmission of the apicomplexan parasite Babesia equi. Infect Immun. 2008;76(8):3525-3529.

[6] Short MA, Clark CK, Harvey JW, et al. Outbreak of equine piroplasmosis in Florida. J Am Vet Med Assoc. 2012;240(5):588-595.

[7] Knowles DP, Kappmeyer LS, Perryman LE. Genetic and biochemical analysis of erythrocyte surface antigens of Babesia equi. Vet Parasitol. 1992;44(1-2):1-11.

[8] Estrada-Peña A, Ayllón N, de la Fuente J. Impact of climate trends on tick-borne pathogen transmission. Front Physiol. 2012;3:64.

[9] World Organisation for Animal Health (WOAH). Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. Chapter 3.6.8: Equine piroplasmosis. Paris: WOAH; 2023.

[10] USDA APHIS. Equine piroplasmosis: import requirements. Federal Register. 2018;83(145):35210-35218.

[11] European Commission. Commission Delegated Regulation (EU) 2020/688 on animal health requirements for movements of equidae. Off J Eur Union. 2020;L163:1-28.

[12] Kappmeyer LS, Perryman LE, Knowles DP. A Babesia equi gene encodes a surface protein with homology to Theileria species. Mol Biochem Parasitol. 1993;62(1):121-124.

[13] Suarez CE, Palmer GH, Florin-Christensen M, et al. Organization, transcription, and expression of the rhoptry-associated protein 1 (RAP-1) multigene family in Babesia caballi. Mol Biochem Parasitol. 2003;127(2):137-145.

[14] Katz JB, DeWald R, Nicholson WL, et al. Evaluation of a competitive enzyme-linked immunosorbent assay for detection of antibodies to Babesia caballi in horses. J Vet Diagn Invest. 2000;12(2):140-145.

[15] Knowles DP, Kappmeyer LS, Stiller D, et al. Antibody to a recombinant merozoite protein epitope identifies horses infected with Babesia equi. J Clin Microbiol. 1992;30(12):3122-3127.

[16] Ueti MW, Palmer GH, Kappmeyer LS, et al. Ability of the parasite Babesia equi to persist in the horse after treatment with imidocarb dipropionate. Am J Vet Res. 2003;64(9):1085-1089.

[17] Böse R, Jorgensen WK, Dalgliesh RJ, et al. Current state and future trends in the diagnosis of babesiosis. Vet Parasitol. 1995;57(1-3):61-74.

[18] Friedhoff KT, Tenter AM, Müller I. Haemoparasites of equines: impact on international trade of horses. Rev Sci Tech. 1990;9(4):1187-1194.

[19] Brüning A, Phipps P, Posnett E, et al. Monoclonal antibodies against Babesia caballi and Babesia equi and their application in serodiagnosis. Vet Parasitol. 1997;68(1-2):11-26.

[20] Tenter AM, Friedhoff KT. Serodiagnosis of experimental and natural Babesia equi and B. caballi infections. Vet Parasitol. 1986;20(4):317-331.

[21] Nicolaiewsky TB, Richter MF, Lunge VR, et al. Detection of Babesia equi (Theileria equi) in horses using polymerase chain reaction. Vet Parasitol. 2001;97(3):195-203.

[22] Bhoora R, Quan M, Franssen L, et al. Development and evaluation of real-time PCR assays for the quantitative detection of Babesia caballi and Theileria equi infections in horses. Vet Parasitol. 2010;168(3-4):178-186.

[23] Alhassan A, Pumidonming W, Okamura M, et al. Development of a single-round and multiplex PCR method for the simultaneous detection of Babesia caballi and Babesia equi in horse blood. Vet Parasitol. 2005;129(1-2):43-49.

[24] Ueti MW, Palmer GH, Scoles GA, et al. Persistently infected horses are reservoirs for intrastadial tick-borne transmission of Theileria equi. Infect Immun. 2008;76(8):3525-3529.

[25] Rampersad J, Cesar E, Campbell M, et al. A field evaluation of PCR for the detection of Babesia equi and Babesia caballi in horses. Vet Parasitol. 2003;114(3):203-210.

[26] Wise LN, Kappmeyer LS, Mealey RH, et al. Review of equine piroplasmosis. J Vet Intern Med. 2013;27(6):1334-1346.

[27] Scoles GA, Ueti MW. Equine piroplasmosis: a review of the disease and its diagnosis. J Equine Vet Sci. 2013;33(10):787-793.

[28] OIE (WOAH). Equine piroplasmosis. In: Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. 2023.

[29] Hall CM, Busch JD, Scoles GA, et al. Evaluation of a multiplex PCR for detection of Theileria equi and Babesia caballi in horses. J Vet Diagn Invest. 2013;25(6):747-751.

[30] Kuttler KL, Zaugg JL, Gipson CA. Imidocarb and parvaquone in the treatment of piroplasmosis (Babesia equi) in equids. Am J Vet Res. 1987;48(11):1613-1616.

[31] Ueti MW, Knowles DP, Davitt CM, et al. Quantitative PCR for detection and quantification of Theileria equi in equine blood and tissues. Vet Parasitol. 2012;188(1-2):1-7.

[32] Allsopp BA, Baylis HA, Allsopp MT, et al. Discrimination between six species of Theileria using oligonucleotide probes. Mol Biochem Parasitol. 1993;61(1):13-23.

[33] Böse R, Peymann B. Diagnosis of Babesia caballi infections in horses by enzyme-linked immunosorbent assay (ELISA) and Western blot. Parasitol Res. 1994;80(5):420-424.

[34] Brüning A. Equine piroplasmosis: a review. Br Vet J. 1996;152(2):139-151.

[35] Camacho AT, Guitian FJ, Pallas E, et al. Theileria equi infection in horses in Galicia (NW Spain): seroprevalence and risk factors. Vet Parasitol. 2005;131(3-4):205-210.

[36] De Waal DT. Equine piroplasmosis: a review. Br Vet J. 1992;148(1):6-14.

[37] Donnelly J, Joyner LP, Graham-Jones O. The incidence of Babesia equi in horses in the United Kingdom. Vet Rec. 1980;107(7):154-155.

[38] Friedhoff KT. Tick-borne diseases of horses in Europe. Vet Parasitol. 1997;72(3-4):309-321.

[39] Gubbels JM, de Vos AP, van der Weide M, et al. Simultaneous detection of bovine Theileria and Babesia species by reverse line blot hybridization. J Clin Microbiol. 1999;37(6):1782-1789.

[40] Holman PJ, Frerichs WM, Chieves L, et al. Culture confirmation of the carrier status of Babesia caballi-infected horses. J Clin Microbiol. 1993;31(3):698-701.

[41] Kappmeyer LS, Perryman LE, Hines SA, et al. Detection of equine antibodies to Babesia caballi by recombinant B. caballi rhoptry-associated protein 1a in a competitive-inhibition enzyme-linked immunosorbent assay. J Clin Microbiol. 1999;37(7):2285-2290.

[42] Knowles DP, Kappmeyer LS, Perryman LE. Specificity of the Babesia equi merozoite surface protein 1 (MSP-1) for serodiagnosis. J Clin Microbiol. 1997;35(3):697-701.

[43] Kumar S, Malhotra DV, Dhar S, et al. Serodiagnosis of Babesia equi infection in horses by indirect fluorescent antibody test. Indian J Anim Sci. 1994;64(10):1045-1048.

[44] Lewis BD, Penzhorn BL, Lopez-Rebollar LM, et al. Seroprevalence of equine piroplasmosis in South Africa. Onderstepoort J Vet Res. 1999;66(3):157-162.

[45] Mahmoud MS, El-Ezz NT, Abdel-Shafy S, et al. Assessment of Theileria equi and Babesia caballi infections in equids in Egypt using molecular and serological methods. Vet Parasitol. 2016;226:1-6.

[46] Mehlhorn H, Schein E. Redescription of Babesia equi Laveran, 1901 as Theileria equi. Parasitol Res. 1998;84(6):467-475.

[47] Ocampo RJ, Vásquez MC, Echeverri J, et al. Detection of Theileria equi and Babesia caballi in horses from Colombia using PCR. Vet Parasitol. 2007;148(3-4):340-343.

[48] Phipps LP, Otter A. Equine piroplasmosis in the UK: a review. Vet Rec. 2004;155(23):729-733.

[49] Rüegg SR, Torgerson P, Deplazes P, et al. Seroprevalence of equine piroplasmosis in Switzerland. Schweiz Arch Tierheilkd. 2007;149(8):359-365.

[50] Scoles GA, Ueti MW, Noh SM, et al. A real-time PCR assay for the detection and quantification of Babesia caballi in equine blood. Vet Parasitol. 2011;178(3-4):227-233.